B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.32
    -1.16 (-3.81%)

    Market Cap: $3.03B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(15/27)
    Avg Surprise
    -36.16%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.17
    Range$-1.28 - $-1.05
    13 analysts
    EPS Revisions
    4
    0
    7d
    4
    5
    30d
    EPS Estimate Drift
    90d ago$-1.18-1.0%
    60d ago$-1.18-1.0%
    30d ago$-1.17-0.4%
    7d ago$-1.17+0.0%
    Current$-1.17
    Revenue Consensus
    $10M
    Range$494900 - $32M
    12 analysts
    Dec 31, 2026
    EPS Consensus$-1.15
    Range$-1.45 - $-0.93
    14 analysts
    Revenue Consensus
    $9M
    Range$-39383820 - $56M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.15---
    Sep 26EST
    		-$-1.17---
    Jun 26
    		$-1.18$1.00-218.00%Miss-18.0%
    Mar 26
    		$-0.91$-1.01+9.90%Beat+26.6%
    Dec 25
    		$2.33$-1.01+330.69%Beat+313.8%
    Sep 25
    		$-1.10$-1.01-8.91%Miss+6.0%
    Jun 25
    		$-1.00$-1.09+8.26%Beat+9.9%
    Mar 25
    		$-1.24$-1.17-5.98%Miss-2.5%
    Dec 24
    		$-1.09$-1.22+10.35%Beat-163.0%
    Sep 24
    		$-1.17$-1.18+0.85%Beat+4.1%
    Jun 24
    		$-1.11$-1.12+0.89%Beat-2.8%
    Mar 24
    		$-1.21$-1.39+12.95%Beat+9.0%
    Dec 23
    		$1.73$-1.01+271.29%Beat+420.4%
    Sep 23
    		$-1.22$-1.27+3.94%Beat+21.8%
    Jun 23
    		$-1.08$-1.38+21.74%Beat-5.9%
    Mar 23
    		$-1.33$-1.30-2.31%Miss-31.7%
    Dec 22
    		$-0.54N/A+59.40%Beat+43.2%
    Sep 22
    		$-1.56$-1.09-43.12%Miss-271.4%
    Jun 22
    		$-1.02$-1.02+0.00%Beat+17.1%
    Mar 22
    		$-1.01$-1.34+24.63%Beat+69.9%
    Dec 21
    		$-0.95$-1.03+7.77%Beat+43.8%
    Sep 21
    		$-0.42$-0.72+41.67%Beat+39.1%
    Jun 21
    		$-1.23$-0.74-66.22%Miss-78.3%
    Mar 21
    		$-3.35$-0.75-346.67%Miss-225.2%
    Dec 20
    		$-1.69$-0.67-152.24%Miss+62.2%
    Sep 20
    		$-0.69$-0.54-27.78%Miss+52.1%
    Jun 20
    		$-0.69$-0.51-35.29%Miss-53.3%
    Mar 20
    		$-1.03$-0.48-114.58%Miss-
    Dec 19
    		$-4.47$-0.52-759.62%Miss-
    Sep 19
    		$-1.44$0.00N/AMiss-
    Jun 19
    		$-0.45$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-34.09EV/EBITDA-7.03x
    Price/FCF-8.21xFCF Yield-12.19%
    Profitability
    Profit Margin-55.40%Operating Margin-25827.00%
    ROE-8.18%ROIC-25.65%
    Financial Health
    Debt/Equity0.10xInterest Coverage9.77x
    Current Ratio14.57xQuick Ratio14.57x
    Trading Statistics
    Beta2.21Avg Volume1.64M
    52-Week High$38.2652-Week Low$16.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$29.02
    SMA 20$28.02
    SMA 50$29.83
    SMA 200$28.34
    EMA 10$29.16
    EMA 20$28.62
    EMA 50$28.93
    EMA 200$28.02

    MACD

    Line: 0.38Signal: -0.07Hist: 0.44

    ADX

    ADX: 19.5+DI: 24.5-DI: 17.3

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down24.0
    PSAR$28.18

    Bollinger Bands

    Upper Band$31.02
    Lower Band$25.02
    %B Position2140%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    52.9

    Momentum Oscillators

    Stoch %K74.3
    Stoch %D77.8
    Williams %R-37.4
    ROC (10d)9.6%
    Momentum2.57
    CCI (20d)91.2
    MFI (14d)44.6

    Volatility Measures

    ATR (14d)$1.65(5.6%)
    StdDev (20d)1.50
    Hist Vol69.5%(High)

    Volume Flow

    VWAP$29.61
    OBV3.2M
    AD Line-54.7M
    CMF (20d)0.103

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.8x
    VWMA (20d)$28.18

    Pivot Points

    R3$32.06
    R2$31.44
    R1$30.96
    Pivot Point$30.34
    S1$29.86
    S2$29.24
    S3$28.76

    Advanced Oscillators

    TSI5.78
    Ultimate Osc56.0
    KST4.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$490,000$31.74M$114.11M$9.70M$8.47M$7.47M$30.07M$14.27M$11.77M$7.41M$316.19M$17.19M
    Cost of Revenue$0$0$5.67M$0$0$0$101.44M$0$0$0$140.08M$0
    Gross Profit$490,000$31.74M$114.11M$9.70M$8.47M$7.47M$30.07M$14.27M$11.77M$7.41M$316.19M$17.19M
    Operating Expenses$127.04M$138.95M$131.50M$136.51M$128.62M$126.78M$130.08M$120.80M$116.67M$111.54M$183.33M$125.46M
    R&D$95.10M$104.52M$99.28M$109.77M$101.76M$98.82M$101.44M$94.26M$87.04M$84.82M$140.08M$100.05M
    SG&A$31.95M$34.43M$32.28M$26.74M$26.86M$27.94M$28.66M$26.52M$29.63M$26.72M$43.26M$25.41M
    Operating Income$-126,553,000$-107,215,000$-17,445,000$-126,811,000$-120,151,000$-119,286,000$-100,037,000$-106,504,000$-104,895,000$-104,132,000$132.86M$-108,267,000
    Interest Income$455,000$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-7,487,000$-9,867,000$-10,640,000$-10,903,000$-12,326,000$-9,864,000$-10,928,000$-12,127,000$-14,190,000$-11,849,000$-12,064,000$-12,698,000
    Income Before Tax$-122,678,000$-94,318,000$244.30M$-112,728,000$-102,138,000$-108,330,000$-90,354,000$-96,668,000$-91,012,000$-98,669,000$47.70M$-96,088,000
    Income Tax Expense$0$0$0$0$0$0$0$0$39,000$0$0$0
    Net Income$-122,678,000$-94,318,000$244.30M$-112,728,000$-102,138,000$-108,330,000$-90,354,000$-96,668,000$-91,051,000$-98,669,000$142.80M$-96,088,000
    EBITDA$-127,751,000$-101,308,000$-19,134,000$-122,304,000$-113,544,000$-116,488,000$-100,506,000$-108,916,000$-105,552,000$-111,663,000$130.11M$-111,483,000
    EBIT$-130,620,000$-104,185,000$-21,544,000$-123,631,000$-114,464,000$-118,167,000$-101,309,000$-108,768,000$-105,202,000$-110,518,000$132.10M$-108,786,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BEAM

    News

    H.C. Wainwright reiterates Beam Therapeutics stock rating at buy

    H.C. Wainwright has reaffirmed its Buy rating and $80.00 price target for Beam Therapeutics (NASDAQ: BEAM), noting the company's strong cash position and pipeline progress. Despite the stock trading above its Fair Value according to InvestingPro data, the firm highlighted advancements in BEAM-302, risto-cel, and FDA clearance for BEAM-304. Beam Therapeutics reported $1.15 billion in cash as of June 30, providing a runway into mid-2029.

    Investing.com•8/25/26•
    Bullish

    H.C. Wainwright reiterates Beam Therapeutics stock rating at buy

    H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc (NASDAQ:BEAM), following a 72% stock return over the past year. The firm highlighted progress on key clinical programs including BEAM-302 for AATD, risto-cel for sickle cell disease, and BEAM-304 for phenylketonuria, with a biologics license application for risto-cel on track for year-end 2026. Beam Therapeutics reported $1.15 billion in cash as of June 30, with a runway into mid-2029, though analysts do not anticipate profitability this year.

    Investing.com•8/25/26•
    Neutral

    Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2% - Here's What Happened

    Beam Therapeutics (NASDAQ:BEAM) saw its stock price drop 6.2% to $27.26 following a significant earnings miss. The company reported an EPS loss of $1.18 against an expected $1.11 loss, and revenue of $0.49 million, far below estimates of $16.37 million, marking a 94.2% year-over-year decline. Despite the poor financial results, analyst sentiment remains a "Moderate Buy" with an average price target of $49.00.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Should You Buy?

    Beam Therapeutics (NASDAQ:BEAM) shares gapped up 4.6% to $28.41, opening higher than its previous close of $26.57, despite reporting weaker-than-expected quarterly results with a significant revenue drop and a larger-than-anticipated loss per share. Analysts hold a "Moderate Buy" rating with a $49 price target, although company insiders have sold a substantial amount of shares recently. Institutional investors, however, maintain a strong ownership of 99.68% in the company.

    MarketBeat•8/19/26•
    Neutral

    Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM

    Alphabet Inc. has acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM) during the second quarter, purchasing 321,604 shares valued at approximately $11.0 million, representing 0.31% ownership. Despite this institutional investment, Beam Therapeutics reported a quarterly loss and significant revenue decline, missing analyst estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.00, though recent insider selling has also been noted.

    MarketBeat•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About BEAM

    Does BEAM pay dividends?
    Beam Therapeutics Inc (BEAM) does not currently pay a regular dividend.
    What is BEAM's market cap?
    Beam Therapeutics Inc (BEAM) has a market capitalization of $3.03B with a current stock price of $29.32.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In